VentrAssistTM LVAD for the Treatment of Advanced Heart Failure - Destination Therapy

Ventracor225 enrolled

Overview

The purpose of this study is to evaluate the safety and effectiveness of LVADs in providing long-term circulatory support for patients who have chronic stage D heart failure and are ineligible for a heart transplant. This is a multi-center, prospective, randomized, controlled clinical trial, which is comprised of two independent modules.

Currently, patients with Stage D heart failure who are not transplant candidates are treated with a spectrum of therapies, including specialized medical management as well as mechanical support with an LVAD approved by FDA for destination therapy. However, there is substantial variation in the therapeutic approaches employed to treat these patients, with relatively low numbers of patients receiving DT LVAD therapy to date. Therefore, the VentrAssist DT trial is designed to provide maximal flexibility to the investigators/clinicians to incorporate their clinical judgment in managing these complex patients.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

225

Conditions

End-stage Heart Failure Cardiomyopathies

Interventions

VentrAssistTM Left Ventricular Assist DeviceDEVICE

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria (The following are general criteria; detailed criteria are included in the study protocol): * Eligible for either the VentrAssist or an FDA-approved DT LVAD * LVEF \<=25% * Stage D heart failure * Ineligible for cardiac transplantation * Treated with standard heart failure therapy Exclusion Criteria (The following are general criteria; detailed criteria are included in the study protocol): * Contraindication to LVAD implantation * Contraindication to anticoagulant or anti-platelet agents. * Pre-existing mechanical circulatory support other than intra-aortic balloon pump * Therapy with an investigational intervention at the time of screening * A condition, other than heart failure, which would limit survival to less than 2 years

Locations (27)

Outcomes

Primary Outcomes

Module A: Survival without a disabling stroke.

Module B: A composite endpoint of disabling stroke-free survival without device replacement or repair due to failure of the device to provide adequate circulatory support.

Secondary Outcomes

•Safety •Functional Status and Hospitalizations •Quality of Life and Neurocognitive Assessment

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.